Breaking News

OctoPlus, The Medicines Co. Sign Development Contract

OctoPlus N.V. has signed a development and manufacturing contract with U.S.-based The Medicines Company.

OctoPlus N.V. has signed a development and manufacturing contract with U.S.-based The Medicines Company. Under the contract terms, OctoPlus will perform process development and clinical manufacturing for The Medicines Co. related to MDCO-216 (ApoA-I Milano/phospholipid complex).

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. OctoPlus also offers drug delivery technologies for the development of controlled release versions of existing or new drugs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters